| TAZEMETOSTAT HYDROBROMIDE | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 4.0 | - | DailyMed |
| TAZEMETOSTAT | Small molecule | urothelial carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | multiple myeloma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | urinary bladder cancer | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | nasal cavity and paranasal sinus carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | prostate cancer | Histone-lysine N-methyltransferase EZH2 inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | mesothelioma | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Completed | ClinicalTrials |
| TAZEMETOSTAT HYDROBROMIDE | Small molecule | sarcoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 4.0 | - | FDA |
| TAZEMETOSTAT | Small molecule | head and neck squamous cell carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | small cell lung carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | non-Hodgkins lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | sarcoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 4.0 | - | FDA |
| TAZEMETOSTAT | Small molecule | diffuse large B-cell lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | non-small cell lung carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | acute myeloid leukemia | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | neoplasm of mature B-cells | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 4.0 | - | DailyMed |
| TAZEMETOSTAT | Small molecule | diffuse large B-cell lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Completed | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | metastatic prostate cancer | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | epithelioid sarcoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| GSK2816126 | Small molecule | cancer | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | follicular lymphoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | neoplasm | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT HYDROBROMIDE | Small molecule | prostate cancer | Histone-lysine N-methyltransferase EZH2 inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| TAZEMETOSTAT HYDROBROMIDE | Small molecule | small cell lung carcinoma | Histone-lysine N-methyltransferase EZH2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TAZEMETOSTAT | Small molecule | neoplasm | Histone-lysine N-methyltransferase EZH2 inhibitor | 4.0 | - | ATC |
| TAZEMETOSTAT | Small molecule | neoplasm of mature B-cells | Histone-lysine N-methyltransferase EZH2 inhibitor | 2.0 | Completed | ClinicalTrials |